Doxorubicin in the 1980s: Is There Still Room for Clinical Investigation?
| Autor: | G. Beretta, C. Praga, P. Zanon, O. Bawa, D. Tabanelli |
|---|---|
| Rok vydání: | 1982 |
| Předmět: |
Drug
Oncology medicine.medical_specialty business.industry media_common.quotation_subject medicine.disease Inflammatory breast cancer Frequent use Intraarterial infusion Clinical investigation Internal medicine Intravesical instillation medicine Medroxyprogesterone acetate Doxorubicin business media_common medicine.drug |
| Zdroj: | Anthracycline Antibiotics in Cancer Therapy ISBN: 9789400976320 |
| DOI: | 10.1007/978-94-009-7630-6_36 |
| Popis: | Doxorubicin (DXR) was a successful drug in its first decade, and, to the present, it has seen an increasingly frequent use on a clinical level. Certainly the major contribution to such increasing use has been the continuing clinical investigation (1–7). The main strategic approaches that were followed in the 1970s for the clinical development of DXR are shown in Table 1. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|